CN112890185A - 一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法 - Google Patents
一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法 Download PDFInfo
- Publication number
- CN112890185A CN112890185A CN202110130186.2A CN202110130186A CN112890185A CN 112890185 A CN112890185 A CN 112890185A CN 202110130186 A CN202110130186 A CN 202110130186A CN 112890185 A CN112890185 A CN 112890185A
- Authority
- CN
- China
- Prior art keywords
- dry powder
- lithocarpus litseifolius
- parts
- extract dry
- leaf extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001365741 Lithocarpus litseifolius Species 0.000 title claims abstract description 134
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 210000004369 blood Anatomy 0.000 title claims abstract description 32
- 239000008280 blood Substances 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000001603 reducing effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 142
- 240000000249 Morus alba Species 0.000 claims abstract description 44
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 44
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 36
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 21
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 18
- 239000001689 FEMA 4674 Substances 0.000 claims abstract description 16
- 241000913745 Spatholobus Species 0.000 claims abstract description 16
- 229930182647 Trilobatin Natural products 0.000 claims abstract description 16
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019139 phlorizin Nutrition 0.000 claims abstract description 16
- GSTCPEBQYSOEHV-QNDFHXLGSA-N trilobatin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GSTCPEBQYSOEHV-QNDFHXLGSA-N 0.000 claims abstract description 16
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940126902 Phlorizin Drugs 0.000 claims description 7
- 229930003935 flavonoid Natural products 0.000 claims description 7
- 235000017173 flavonoids Nutrition 0.000 claims description 7
- 150000002215 flavonoids Chemical class 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 241000219781 Pueraria montana var. lobata Species 0.000 claims 3
- 239000004067 bulking agent Substances 0.000 claims 1
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 17
- 244000046146 Pueraria lobata Species 0.000 abstract description 15
- IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 abstract description 15
- 102000004877 Insulin Human genes 0.000 abstract description 11
- 108090001061 Insulin Proteins 0.000 abstract description 11
- 229940125396 insulin Drugs 0.000 abstract description 11
- IOUVKUPGCMBWBT-DARKYYSBSA-N Phloridzin Natural products O[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-DARKYYSBSA-N 0.000 abstract description 9
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000003914 insulin secretion Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000007939 sustained release tablet Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 7
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 238000002137 ultrasound extraction Methods 0.000 description 5
- 239000000811 xylitol Substances 0.000 description 5
- 235000010447 xylitol Nutrition 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- 229960002675 xylitol Drugs 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229950008882 polysorbate Drugs 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 241000208140 Acer Species 0.000 description 3
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 244000102051 Acer ginnala Species 0.000 description 2
- 235000015988 Acer ginnala Nutrition 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- -1 Novo Nordisk) Chemical compound 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940016591 methylinositol Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KGQLDJQLGLDZQG-UHFFFAOYSA-N 2-O-galloyl-6-O-trigalloyl-1,5-anhydro-D-glucitol Natural products OC1C(O)C(COC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(OC(=O)c4cc(O)c(O)c(O)c4)c3)c2)OCC1OC(=O)c5cc(O)c(O)c(O)c5 KGQLDJQLGLDZQG-UHFFFAOYSA-N 0.000 description 1
- NPPDZMXIFYVPRD-UHFFFAOYSA-N 3,3,7-trihydroxy-6-methoxy-2-phenyl-4a,5-dihydro-2h-chromen-4-one Chemical compound OC1(O)C(=O)C2CC(OC)=C(O)C=C2OC1C1=CC=CC=C1 NPPDZMXIFYVPRD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- IGKWMHUOBKCUQU-USJZOSNVSA-N Aceritannin Natural products O[C@@H]1[C@@H](O)[C@H](COC(=O)c2cc(O)c(O)c(O)c2)OC[C@@H]1OC(=O)c3cc(O)c(O)c(O)c3 IGKWMHUOBKCUQU-USJZOSNVSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001080798 Polygala tenuifolia Species 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/20—Aceraceae (Maple family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于保健食品技术领域,具体涉及一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法。其技术要点如下:按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉11~20份,木姜叶柯老叶提取物干粉11~30份,桑叶提取物干粉5~20份,鸡血藤提取物干粉5~10份,桑芽干粉10~30份,葛根提取物干粉10~20份和辅料30~60份。本发明通过木姜叶柯老叶中的根皮苷和木姜叶柯嫩叶中的三叶苷之间的复配使用,减少血糖来源并增加血糖去路,同时配合桑叶中1‑脱氧野尻霉素对α‑糖苷酶的抑制和对胰岛素B细胞分泌胰岛素达到降血糖的效果。
Description
技术领域
本发明属于保健食品技术领域,具体涉及一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法。
背景技术
糖尿病(Diabetes Mellitus,DM)是一种因体内胰岛素绝对或者相对不足所导致的一系列临床综合症。该病在发展进程中还会引起一些并发症,如:低血糖症(Hypoglycemia)、酮症酸中毒(Ketoacidosis)、非酮高渗性昏迷(NonketoticHyperosmolarComa)、心血管疾病、慢性肾衰竭、视网膜病变、神经病变及微血管病变等。
糖尿病治疗常用的药物主要包括:生物药物,如胰岛素(Insulin);化学药物,如磺酰脲类(Sulfonylurea)、双胍类(Biguanide)、格列酮类(Glitazone);和天然药物,如中草药。限于目前尚没有成熟的非注射给药技术,胰岛素的使用仍以注射为主,注射过程中存在安全性风险。其他一些注射给药药物,如胰高血糖素类多肽(Glucagon-like peptide 1,GLP-1)、脂酰基化胰高血糖素类多肽(NN2211,Novo Nordisk)、Exendin-4(Amylin)和聚乙二醇修饰的Exendin-4等,长期给药后虽能有效控制血糖、降低糖化血红蛋白HbA1c 数值和改善β胰岛细胞功能,但由于这些分子同时还作用于中枢神经受体,给药后会产生呕吐和眩晕的症状。一些化学药物虽可降低血糖,但具有不同的副作用或肝、肾毒性,还容易导致心血管并发症的加重。如DPP-IV抑制剂类药物,由于其对生物体内的一大类酶均有抑制作用,会使体内脂肪的分布发生变化,且给药的实际效果也相对较差。现有各种治疗糖尿病的中成药虽有一定的治疗作用,但由于药物作用机理单一或其作用机理及有效成分尚不清楚,药物疗效和药品质量难以得到保证。
有鉴于上述缺陷,本发明人基于从事此类产品设计制造多年丰富的实务经验及专业知识,并配合学理的运用,积极加以研究创新,以期创设一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法,通过木姜叶柯老叶中的根皮苷和木姜叶柯嫩叶中的三叶苷之间的复配使用,减少血糖来源并增加血糖去路,同时配合桑叶中1-脱氧野尻霉素对α-糖苷酶的抑制和对胰岛素B细胞分泌胰岛素达到降血糖的效果。经过不断的研究、设计,并经反复试作样品及改进后,终于创设出确具实用价值的本发明。
发明内容
本发明的第一个目的是提供一种含有木姜叶柯的降血糖组合物,通过木姜叶柯老叶中的根皮苷和木姜叶柯嫩叶中的三叶苷之间的复配使用,减少血糖来源并增加血糖去路,同时配合桑叶中1-脱氧野尻霉素对α-糖苷酶的抑制和对胰岛素B细胞分泌胰岛素达到降血糖的效果,具有产业价值。
本发明的上述技术目的是通过以下技术方案得以实现的:
本发明提供的一种含有木姜叶柯的降血糖组合物,按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉11~20份,木姜叶柯老叶提取物干粉11~30份,桑叶提取物干粉5~20份,鸡血藤提取物干粉5~10份,桑芽干粉10~30份,葛根提取物干粉10~20份和辅料30~60份。
桑叶提取物中含有大量的1-脱氧野尻霉素,通过抑制α-糖苷酶和促进胰岛素B细胞分泌胰岛素,达到降血糖的效果;而木姜叶柯嫩叶中含有大量的三叶苷,木姜叶柯老叶中含有大量的根皮苷,三叶苷与根皮苷在糖的代谢中,能够产生协同作用,在减少血糖来源的同时增加血糖的去路,从而在桑叶提取物的作用下,共同达到降血压、降血脂、降血糖的技术效果;另一方面,本发明提供的组合物中,还含有鸡血藤提取物和桑芽,鸡血藤提取物中含有芒柄花苷和3,7-二羟基-6-甲氧基二氢黄酮醇,能够协同1-脱氧野尻霉素抑制α-糖苷酶的生成,进一步减少血糖来路;桑芽是一种中药,是茶树槭的嫩芽,含有远志醇、茶条槭素A、茶条槭素B、茶条槭素C、甲基肌醇、槲皮甙、槭属鞣质A及其他茶条槭鞣质,如2-O-没食子酰基-6-O- 三没食子酰基-1、5-脱水-D-葡萄糖醇、2,6-双-O-二没食子酰基-1,5-脱水 -D-葡萄糖醇等物质,其中茶条槭鞣质能够有效降低血脂和胆固醇,而远志醇和甲基肌醇能够与三叶苷和根皮苷产生协同作用,增加血糖的去路,达到降低血糖和降低血压的技术效果。
其中,木姜叶柯嫩叶叶龄为1~2周,木姜叶柯老叶叶龄大于8个月。本发明通过对木姜叶柯的嫩叶和老叶的分别提取,控制三叶苷和根皮苷之间的配比,提高三叶苷和根皮苷之间的协同作用效果。
进一步的,辅料由填充剂、粘合剂、分散剂、缓释剂、增溶剂和矫味剂组成。
进一步的,填充剂粘合剂是阿拉伯胶。
进一步的,填充剂是纤维素或甘露醇中的任意一种或两种的混合物。
进一步的,分散剂是环糊精。
进一步的,缓释剂是壳聚糖或丙烯酸树脂中的任意一种。
进一步的,增溶剂是非离子表面活性剂。
进一步的,非离子表面活性剂是椰子油二乙醇酰胺、聚山梨酯、脂肪醇脂、单硬脂酸甘油酯中的任意一种。
进一步的,矫味剂为木糖醇。
进一步的,木姜叶柯嫩叶提取物干粉中,按照质量计算,三叶苷含量是1~5%。
进一步的,木姜叶柯老叶提取物干粉,按照质量计算,根皮苷含量是 2~8%。
进一步的,桑叶提取物干粉中,按照质量计算,1-脱氧野尻霉素含量是 0.1~1%。
进一步的,葛根提取物干粉中,按照质量计算,总黄酮含量是2~5%。
进一步的,鸡血藤提取物干粉中,按照质量计算,芒柄花苷含量是2~5%。
本发明的第二个目的是提供一种含有木姜叶柯的降血糖组合物的制备方法,具有同样的效果。
本发明的上述技术效果是由以下技术方案实现的:
本发明提供的一种降血糖木姜叶柯缓释片的制备方法,将木姜叶柯嫩叶提取物干粉,桑芽干粉,木姜叶柯老叶提取物干粉,桑叶提取物干粉,鸡血藤提取物干粉,葛根提取物干粉和辅料混合均匀得到组合物。
作为上述技术方案的优选,木姜叶柯嫩叶提取物干粉、木姜叶柯老叶干粉、桑叶干粉、鸡血藤提取物干粉或葛根干粉的提取方法为:分别取木姜叶柯嫩叶、木姜叶柯老叶、桑叶、鸡血藤或葛根经干燥、粉碎,按照1:10~20 的固液比用75%的乙醇进行超声波提取,减压浓缩,浓缩液经喷雾干燥即得。
本发明的第三个目的是提供一种含有木姜叶柯的降血糖组合物的应用方法,具有同样的效果。
本发明的上述技术效果是由以下技术方案实现的:
本发明提供的一种含有木姜叶柯的降血糖组合物的应用方法,将组合物制成颗粒、片剂、冲剂或饮料中的任意一种。
作为上述技术方案的优选,将本发明提供的组合物制成片剂,优选将其制成含片或缓释片剂。
综上所述,本发明具有以下有益效果:
本发明提供的一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法,通过木姜叶柯老叶中的根皮苷和木姜叶柯嫩叶中的三叶苷之间的复配使用,减少血糖来源并增加血糖去路,同时配合桑叶中1-脱氧野尻霉素对α-糖苷酶的抑制和对胰岛素B细胞分泌胰岛素达到降血糖的效果。
具体实施方式
为更进一步阐述本发明为达成预定发明目的所采取的技术手段及功效,对依据本发明提出的一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法,其具体实施方式、特征及其功效,详细说明如后。
实施例1:一种含有木姜叶柯的降血糖组合物,按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉15份,木姜叶柯老叶提取物干粉25 份,桑叶提取物干粉10份,鸡血藤提取物干粉5份,桑芽10份,葛根提取物干粉15份和辅料35份。
其中,木姜叶柯嫩叶叶龄为1~2周,木姜叶柯老叶叶龄大于8个月,按照质量计算,木姜叶柯嫩叶提取物干粉中三叶苷含量是1~5%,木姜叶柯老叶提取物干粉中根皮苷含量是2~8%,桑叶提取物干粉中,1-脱氧野尻霉素含量是0.1~1%,葛根提取物干粉中总黄酮含量是2~5%,鸡血藤提取物干粉中芒柄花苷含量是2~5%。
一种含有木姜叶柯的降血糖组合物的制备方法,包括以下操作步骤:将木姜叶柯嫩叶提取物干粉,桑芽干粉,木姜叶柯老叶提取物干粉,桑叶提取物干粉,鸡血藤提取物干粉,葛根提取物干粉和辅料混合均匀得到组合物。
一种含有木姜叶柯的降血糖组合物的应用方法,将其制成缓释片,具体操作如下:在上述获得的组合物中加入湿润剂(羧甲基纤维素钠、羟丙基甲基纤维素、甲基纤维素)制得软材,整粒压片,干燥灭菌即得木姜叶柯缓释片。
实施例2:一种含有木姜叶柯的降血糖组合物,按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉20份,木姜叶柯老叶提取物干粉30 份,桑叶提取物干粉20份,鸡血藤提取物干粉10份,桑芽30份,葛根提取物干粉10份和辅料30份。
其中,木姜叶柯嫩叶叶龄为1~2周,木姜叶柯老叶叶龄大于8个月,按照质量计算,木姜叶柯嫩叶提取物干粉中三叶苷含量是1~5%,木姜叶柯老叶提取物干粉中根皮苷含量是2~8%,桑叶提取物干粉中,1-脱氧野尻霉素含量是0.1~1%,葛根提取物干粉中总黄酮含量是2~5%,鸡血藤提取物干粉中芒柄花苷含量是2~5%。
其中,按照重量份数计算,辅料中各组分为:阿拉伯胶25份,纤维素 25份,环糊精5份,壳聚糖30份,聚山梨酯5份和木糖醇15份。
一种含有木姜叶柯的降血糖组合物的制备方法,包括以下操作步骤:
S1.木姜叶柯嫩叶提取物干粉、木姜叶柯老叶干粉、桑叶干粉、鸡血藤提取物干粉或葛根干粉的提取:分别取木姜叶柯嫩叶、木姜叶柯老叶、桑叶、鸡血藤和葛根经干燥、粉碎,按照1:10的固液比用75%的乙醇进行超声波提取,减压浓缩,浓缩液经喷雾干燥即得;
S2.将木姜叶柯嫩叶提取物干粉,桑芽干粉,木姜叶柯老叶提取物干粉,桑叶提取物干粉,鸡血藤提取物干粉,葛根提取物干粉和辅料混合均匀得到组合物。
一种含有木姜叶柯的降血糖组合物的应用方法,将其制成缓释片,具体操作如下:在上述获得的组合物中加入湿润剂(羧甲基纤维素钠、羟丙基甲基纤维素、甲基纤维素)制得软材,整粒压片,干燥灭菌即得木姜叶柯缓释片。
实施例3:一种含有木姜叶柯的降血糖组合物,按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉20份,木姜叶柯老叶提取物干粉20 份,桑叶提取物干粉20份,鸡血藤提取物干粉5份,桑芽30份,葛根提取物干粉20份和辅料60份。
其中,木姜叶柯嫩叶叶龄为1~2周,木姜叶柯老叶叶龄大于8个月,按照质量计算,木姜叶柯嫩叶提取物干粉中三叶苷含量是1~5%,木姜叶柯老叶提取物干粉中根皮苷含量是2~8%,桑叶提取物干粉中,1-脱氧野尻霉素含量是0.1~1%,葛根提取物干粉中总黄酮含量是2~5%,鸡血藤提取物干粉中芒柄花苷含量是2~5%。
其中,按照重量份数计算,辅料中各组分为:阿拉伯胶15份,纤维素 30份,环糊精10份,壳聚糖30份,单硬脂酸甘油酯5份和木糖醇15份。
一种含有木姜叶柯的降血糖组合物的制备方法,包括以下操作步骤:
S1.木姜叶柯嫩叶提取物干粉、木姜叶柯老叶干粉、桑叶干粉、鸡血藤提取物干粉或葛根干粉的提取:分别取木姜叶柯嫩叶、木姜叶柯老叶、桑叶、鸡血藤和葛根经干燥、粉碎,按照1:18的固液比用75%的乙醇进行超声波提取,减压浓缩,浓缩液经喷雾干燥即得,
S2.将木姜叶柯嫩叶提取物干粉,桑芽干粉,木姜叶柯老叶提取物干粉,桑叶提取物干粉,鸡血藤提取物干粉,葛根提取物干粉和辅料混合均匀得到组合物。
一种含有木姜叶柯的降血糖组合物的应用方法,将其制成缓释片,具体操作如下:在上述获得的组合物中加入湿润剂(羧甲基纤维素钠、羟丙基甲基纤维素、甲基纤维素)制得软材,整粒压片,干燥灭菌即得木姜叶柯缓释片。
实施例4:一种含有木姜叶柯的降血糖组合物,按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉11份,木姜叶柯老叶提取物干粉11 份,桑叶提取物干粉9份,鸡血藤提取物干粉8份,桑芽22份,葛根提取物干粉19份和辅料60份。
其中,木姜叶柯嫩叶叶龄为1~2周,木姜叶柯老叶叶龄大于8个月,按照质量计算,木姜叶柯嫩叶提取物干粉中三叶苷含量是1~5%,木姜叶柯老叶提取物干粉中根皮苷含量是2~8%,桑叶提取物干粉中,1-脱氧野尻霉素含量是0.1~1%,葛根提取物干粉中总黄酮含量是2~5%,鸡血藤提取物干粉中芒柄花苷含量是2~5%。
其中,按照重量份数计算,辅料中各组分为:阿拉伯胶15份,纤维素 30份,环糊精10份,壳聚糖30份,聚山梨酯5份和木糖醇10份。
一种含有木姜叶柯的降血糖组合物的制备方法,包括以下操作步骤:
S1.木姜叶柯嫩叶提取物干粉、木姜叶柯老叶干粉、桑叶干粉、鸡血藤提取物干粉或葛根干粉的提取:分别取木姜叶柯嫩叶、木姜叶柯老叶、桑叶、鸡血藤和葛根经干燥、粉碎,按照1:16的固液比用75%的乙醇进行超声波提取,减压浓缩,浓缩液经喷雾干燥即得,
S2.将木姜叶柯嫩叶提取物干粉,木姜叶柯老叶提取物干粉,桑叶提取物干粉,鸡血藤提取物干粉,葛根提取物干粉和辅料混合均匀。
一种含有木姜叶柯的降血糖组合物的应用方法,将其制成颗粒,具体操作如下:
A1.将木姜叶柯嫩叶提取物干粉11份,木姜叶柯老叶提取物干粉11 份,桑叶提取物干粉9份,鸡血藤提取物干粉8份,桑芽22份,葛根提取物干粉19份和辅料60份溶解于300份60℃的热水,搅拌使其充分溶解,得甜味剂溶液;
A2.趁热将甜味剂溶液以每小时10℃进行降温至30℃,然后以每小时5℃降温至10℃,最后以每小时降低2℃进行降温至4℃,使得甜味剂充分结晶;
A3.将结晶后的甜味剂溶液过滤,取晶体,在温度为60℃下干燥6h,制得颗粒。
实施例5:一种含有木姜叶柯的降血糖组合物,按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉18份,木姜叶柯老叶提取物干粉22 份,桑叶提取物干粉10份,鸡血藤提取物干粉8份,桑芽20份,葛根提取物干粉10份和辅料40份。
其中,木姜叶柯嫩叶叶龄为1~2周,木姜叶柯老叶叶龄大于8个月,按照质量计算,木姜叶柯嫩叶提取物干粉中三叶苷含量是1~5%,木姜叶柯老叶提取物干粉中根皮苷含量是2~8%,桑叶提取物干粉中,1-脱氧野尻霉素含量是0.1~1%,葛根提取物干粉中总黄酮含量是2~5%,鸡血藤提取物干粉中芒柄花苷含量是2~5%。
其中,按照重量份数计算,辅料中各组分为:阿拉伯胶15份,甘露醇 30份,环糊精10份,壳聚糖30份,聚山梨酯5份和木糖醇10份。
一种含有木姜叶柯的降血糖组合物的制备方法,包括以下操作步骤:
S1.木姜叶柯嫩叶提取物干粉、木姜叶柯老叶干粉、桑叶干粉、鸡血藤提取物干粉或葛根干粉的提取:分别取木姜叶柯嫩叶、木姜叶柯老叶、桑叶、鸡血藤和葛根经干燥、粉碎,按照1:10~20的固液比用75%的乙醇进行超声波提取,减压浓缩,浓缩液经喷雾干燥即得,
S2.将木姜叶柯嫩叶提取物干粉,桑芽干粉,木姜叶柯老叶提取物干粉,桑叶提取物干粉,鸡血藤提取物干粉,葛根提取物干粉和辅料混合均匀得到组合物。
一种含有木姜叶柯的降血糖组合物的应用方法,将其制成含有木姜叶柯的降血糖饮料,具体操作如下:
B1.将步骤S2得到的混合物放入纯化水中常压下煎煮1h,过滤得到滤液;
B2.将滤液杀菌、冷却、灌装,即为含有木姜叶柯的降血糖饮料。
技术效果测试:
1.将实施例1至实施例5进行试验,具体试验步骤如下:采用实施例 1~5所制备的组合物用于降血糖试验,测定各组小白鼠的起始血糖浓度,小鼠喂饲4周后,断尾取血用血糖仪测定血糖浓度,并将不服用任何降糖产品的小鼠作为空白对照实施例,结果如下表所示:
表1.小鼠血糖水平检测结
组别 | 起始血糖浓度 | 4周后血糖浓度 |
实施例1 | 5.28±0.58 | 3.85±0.38 |
实施例2 | 5.28±0.58 | 3.72±0.38 |
实施例3 | 5.28±0.58 | 3.77±0.38 |
实施例4 | 5.28±0.58 | 3.78±0.38 |
实施例5 | 5.28±0.58 | 3.74±0.38 |
空白对照实施例 | 5.28±0.58 | 5.28±0.58 |
实验表明,本发明提供的含有木姜叶柯的降血糖组合物具有显著的降血糖作用效果。
2.将实施例1~3得到的缓释片按照溶出度测定法,以0.1mol/L的盐酸900mL为释放介质,,温度(37±0.5)℃,转速100r/min,分别于1,2,4, 6小时取样10mL,同时立即补充释放介质10mL。另取芦丁标准品工作溶液,作为对照品溶液,在420nm波长测量吸光度,绘制标准曲线,求出各个时间点的累积溶出度结果详见表2。
表2.实施例1~3缓释片的缓释度
累计1h释放度/% | 累计2h释放度/% | 累计4h释放度/% | 累计6h释放度/% | |
实施例1 | 20.84 | 50.76 | 76.22 | 98.08 |
实施例2 | 21.14 | 51.35 | 77.41 | 98.14 |
实施例3 | 21.22 | 51.88 | 77.53 | 98.15 |
实验表明本发明的含木姜叶柯的降血糖组合物缓释片具有较好的降血糖效果,同时实验结果显示缓释片释放度符合要求,化学稳定性良好。
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,虽然本发明已以较佳实施例揭露如上,然而并非用以限定本发明,任何熟悉本专业的技术人员,在不脱离本发明技术方案范围内,当可利用上述揭示的技术内容做出些许更动或修饰为等同变化的等效实施例,但凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与修饰,均仍属于本发明技术方案的范围内。
Claims (10)
1.一种含有木姜叶柯的降血糖组合物,其特征在于,按照重量份数计算,包括如下组分:木姜叶柯嫩叶提取物干粉11~20份,木姜叶柯老叶提取物干粉11~30份,桑叶提取物干粉5~20份,鸡血藤提取物干粉5~10份,桑芽干粉10~30份,葛根提取物干粉10~20份和辅料30~60份。
2.根据权利要求1所述的一种含有木姜叶柯的降血糖组合物,其特征在于,所述辅料由填充剂、粘合剂、分散剂、缓释剂、增溶剂和矫味剂组成。
3.根据权利要求2所述的一种含有木姜叶柯的降血糖组合物,其特征在于,所述填充剂是纤维素或甘露醇中的任意一种或两种的混合物。
4.根据权利要求2所述的一种含有木姜叶柯的降血糖组合物,其特征在于,所述缓释剂是壳聚糖或丙烯酸树脂中的任意一种。
5.根据权利要求1所述的一种含有木姜叶柯的降血糖组合物,其特征在于,所述木姜叶柯嫩叶提取物干粉中,按照质量计算,三叶苷含量是1~5%。
6.根据权利要求1所述的一种含有木姜叶柯的降血糖组合物,其特征在于,所述木姜叶柯老叶提取物干粉,按照质量计算,根皮苷含量是2~8%。
7.根据权利要求1所述的一种含有木姜叶柯的降血糖组合物,其特征在于,所述桑叶提取物干粉中,按照质量计算,1-脱氧野尻霉素含量是0.1~1%。
8.根据权利要求1所述的一种含有木姜叶柯的降血糖组合物,其特征在于,所述葛根提取物干粉中,按照质量计算,总黄酮含量是2~5%。
9.根据权利要求1所述的一种含有木姜叶柯的降血糖组合物的制备方法,其特征在于,将木姜叶柯嫩叶提取物干粉,木姜叶柯老叶提取物干粉,桑芽干粉,桑叶提取物干粉,鸡血藤提取物干粉,葛根提取物干粉和辅料混合均匀得到组合物。
10.根据权利要求9所述的一种含有木姜叶柯的降血糖组合物的应用方法,其特征在于,将所述组合物制成颗粒、片剂、冲剂或饮料中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110130186.2A CN112890185A (zh) | 2021-01-29 | 2021-01-29 | 一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110130186.2A CN112890185A (zh) | 2021-01-29 | 2021-01-29 | 一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112890185A true CN112890185A (zh) | 2021-06-04 |
Family
ID=76121661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110130186.2A Pending CN112890185A (zh) | 2021-01-29 | 2021-01-29 | 一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112890185A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115474640A (zh) * | 2022-09-30 | 2022-12-16 | 良甜生物医药科技江苏有限公司 | 一种功能性木姜叶柯茶饮及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813910A (zh) * | 2005-02-05 | 2006-08-09 | 北京北大维信生物科技有限公司 | 一种具有降糖作用的药物组合物及其制备方法 |
KR20100102366A (ko) * | 2009-03-11 | 2010-09-24 | 이종훈 | 혈당강하 및 통증완화용 건강보조식품 조성물 |
CN107802770A (zh) * | 2017-11-23 | 2018-03-16 | 武汉贝贝亮生物科技有限公司 | 平衡代谢系统根治早期ⅱ型糖尿病的中药和保健品 |
CN109007128A (zh) * | 2018-08-30 | 2018-12-18 | 广西壮族自治区林业科学研究院 | 一种抗氧化降血糖木姜叶柯茶 |
CN110150623A (zh) * | 2019-05-31 | 2019-08-23 | 广西苷亮健生物科技有限公司 | 一种木姜叶柯甜味颗粒及其制备方法 |
CN110384709A (zh) * | 2018-04-20 | 2019-10-29 | 中国科学院上海药物研究所 | 含有根皮苷和1-脱氧野尻霉素的组合物及其应用 |
CN110946196A (zh) * | 2019-11-22 | 2020-04-03 | 中南大学 | 木姜叶柯冲剂及制备方法 |
-
2021
- 2021-01-29 CN CN202110130186.2A patent/CN112890185A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813910A (zh) * | 2005-02-05 | 2006-08-09 | 北京北大维信生物科技有限公司 | 一种具有降糖作用的药物组合物及其制备方法 |
KR20100102366A (ko) * | 2009-03-11 | 2010-09-24 | 이종훈 | 혈당강하 및 통증완화용 건강보조식품 조성물 |
CN107802770A (zh) * | 2017-11-23 | 2018-03-16 | 武汉贝贝亮生物科技有限公司 | 平衡代谢系统根治早期ⅱ型糖尿病的中药和保健品 |
CN110384709A (zh) * | 2018-04-20 | 2019-10-29 | 中国科学院上海药物研究所 | 含有根皮苷和1-脱氧野尻霉素的组合物及其应用 |
CN109007128A (zh) * | 2018-08-30 | 2018-12-18 | 广西壮族自治区林业科学研究院 | 一种抗氧化降血糖木姜叶柯茶 |
CN110150623A (zh) * | 2019-05-31 | 2019-08-23 | 广西苷亮健生物科技有限公司 | 一种木姜叶柯甜味颗粒及其制备方法 |
CN110946196A (zh) * | 2019-11-22 | 2020-04-03 | 中南大学 | 木姜叶柯冲剂及制备方法 |
Non-Patent Citations (1)
Title |
---|
刘伟: "中药提取物抑制α-葡萄糖苷酶的活性研究", 《黑龙江医药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115474640A (zh) * | 2022-09-30 | 2022-12-16 | 良甜生物医药科技江苏有限公司 | 一种功能性木姜叶柯茶饮及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102458434B (zh) | 用于提高皂素的生物利用度的组合物 | |
CN107412721B (zh) | 一种降血糖苦瓜多肽复方胶囊及其制备方法 | |
CN103734751A (zh) | 一种复合膳食纤维及其制法 | |
CN112156156B (zh) | 一种兽用中药抗病毒口服液及其制备方法 | |
CN112890185A (zh) | 一种含有木姜叶柯的降血糖组合物及其制备方法和应用方法 | |
CN107073026A (zh) | 用于治疗高血糖疾病的生物活性物质组合 | |
CN101244118B (zh) | 一种天然植物提取物的制备方法 | |
CN109939120A (zh) | 含烟酰胺单核苷酸和罗汉果苷的组合物及其应用 | |
CN107536871A (zh) | 一种用于降血糖的中药提取物的制备方法 | |
CN103766901A (zh) | 一种穿心莲丙素在制备减肥食品或药品中的应用 | |
CN108835636B (zh) | 一种辅助降血糖的山楂保健食品 | |
CN112716988A (zh) | 倒心盾翅藤提取物在制备预防和/或治疗糖尿病肾病的药物中的应用 | |
CN115040471B (zh) | 一种含枸杞多糖营养视网膜神经的产品及其制备方法 | |
CN100453073C (zh) | 复方半边莲滴丸及其制备方法 | |
CN106309528B (zh) | 一种隔山消提取物、其制备方法及在降血糖方面的应用 | |
CN110384709A (zh) | 含有根皮苷和1-脱氧野尻霉素的组合物及其应用 | |
Mujeeb et al. | Antidiabetic activity of the aqueous extract of Chlorophytum borivilianum L. in streptozotocin induced-hyperglycemic rats: a preliminary study | |
CN107513092A (zh) | 一种丙二酰基人参皂苷Rb1的制备方法及其医用用途 | |
CN103271349B (zh) | 含活性成分人参片及其生产方法 | |
CN110050930B (zh) | 一种牛蒡固体饮料及其制备方法 | |
CN115068559B (zh) | 一种具有辅助降血糖功效的植物基复方口服液及其制备方法 | |
CN114832042B (zh) | 一种中药组合物及其在制备治疗降血糖药物中的应用 | |
TWI387461B (zh) | 野薑花(hedychium coronarium koenig)地上部份於降低血糖之用途;野薑花地上部份之萃取物及組合物與其用途 | |
SG181409A1 (en) | A composition for treating hyperglycemia and a process thereof | |
CN100588326C (zh) | 一种赤藓糖醇口香糖 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210604 |